Assertio Holdings, Inc. (ASRT)
USD 0.6
(2.7%)
USD 0.6
(2.7%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -222.44 Million USD | -41.71% |
| 2022 | 72.53 Million USD | 128.98% |
| 2021 | 38.78 Million USD | 257.08% |
| 2020 | -3.2 Million USD | -124.16% |
| 2019 | -61.12 Million USD | -37.23% |
| 2018 | 213.15 Million USD | 124.49% |
| 2017 | 74.05 Million USD | -43.5% |
| 2016 | 133.76 Million USD | 3518.97% |
| 2015 | 35.93 Million USD | -98.53% |
| 2014 | 252.63 Million USD | 1715.44% |
| 2013 | 16.67 Million USD | 148.06% |
| 2012 | -27.27 Million USD | -204.57% |
| 2011 | 71.67 Million USD | -308.38% |
| 2010 | 4.9 Million USD | 121.23% |
| 2009 | -20.21 Million USD | 10.34% |
| 2008 | -13.59 Million USD | -269.67% |
| 2007 | 48.4 Million USD | 134.35% |
| 2006 | -40.22 Million USD | -52.19% |
| 2005 | -25.37 Million USD | -7.3% |
| 2004 | -24.63 Million USD | 13.12% |
| 2003 | -28.35 Million USD | 37.93% |
| 2002 | -27.68 Million USD | -233.19% |
| 2001 | -13.71 Million USD | -174.83% |
| 2000 | -7.17 Million USD | -169.6% |
| 1999 | -4.84 Million USD | 317.21% |
| 1998 | -2.83 Million USD | -200.0% |
| 1997 | -1 Million USD | -120.0% |
| 1996 | -500 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 2.11 Million USD | 108.06% |
| 2024 Q2 | 4.99 Million USD | 86.57% |
| 2023 FY | - USD | -41.71% |
| 2023 Q2 | 19.8 Million USD | -6.14% |
| 2023 Q3 | 6.55 Million USD | -66.89% |
| 2023 Q4 | -1.22 Million USD | -118.68% |
| 2023 Q1 | 21.09 Million USD | -29.44% |
| 2022 FY | - USD | 128.98% |
| 2022 Q4 | 29.9 Million USD | 62.7% |
| 2022 Q1 | 22.44 Million USD | 53.19% |
| 2022 Q2 | 20.16 Million USD | -10.19% |
| 2022 Q3 | 18.37 Million USD | -8.84% |
| 2021 Q2 | -4.39 Million USD | -128.0% |
| 2021 Q3 | 13.69 Million USD | 411.85% |
| 2021 Q4 | 14.65 Million USD | 7.04% |
| 2021 FY | - USD | 257.08% |
| 2021 Q1 | 15.67 Million USD | 597.69% |
| 2020 Q2 | -14.87 Million USD | -25.13% |
| 2020 Q3 | 1.85 Million USD | 112.48% |
| 2020 FY | - USD | -124.16% |
| 2020 Q1 | -11.88 Million USD | -134.26% |
| 2020 Q4 | 2.24 Million USD | 21.07% |
| 2019 Q4 | 34.7 Million USD | 138.54% |
| 2019 Q2 | 27.89 Million USD | -4.03% |
| 2019 Q3 | 14.54 Million USD | -47.84% |
| 2019 FY | - USD | -37.23% |
| 2019 Q1 | 29.06 Million USD | 101.2% |
| 2018 Q3 | 41.12 Million USD | 51.77% |
| 2018 FY | - USD | 124.49% |
| 2018 Q1 | 87.5 Million USD | 3697.83% |
| 2018 Q2 | 27.1 Million USD | -69.03% |
| 2018 Q4 | 14.44 Million USD | -64.88% |
| 2017 Q4 | 2.3 Million USD | -91.8% |
| 2017 FY | - USD | -43.5% |
| 2017 Q1 | 19.93 Million USD | -54.5% |
| 2017 Q2 | 25.99 Million USD | 30.42% |
| 2017 Q3 | 28.08 Million USD | 8.03% |
| 2016 FY | - USD | 3518.97% |
| 2016 Q4 | 43.81 Million USD | 54.23% |
| 2016 Q3 | 28.4 Million USD | -24.03% |
| 2016 Q2 | 37.39 Million USD | 59.24% |
| 2016 Q1 | 23.48 Million USD | 180.99% |
| 2015 Q2 | 9.57 Million USD | 240.19% |
| 2015 Q1 | -6.83 Million USD | -104.26% |
| 2015 Q3 | 30.93 Million USD | 222.98% |
| 2015 Q4 | -28.99 Million USD | -193.73% |
| 2015 FY | - USD | -98.53% |
| 2014 FY | - USD | 1715.44% |
| 2014 Q4 | 160.5 Million USD | 824.95% |
| 2014 Q3 | 17.35 Million USD | -41.36% |
| 2014 Q2 | 29.59 Million USD | -21.48% |
| 2014 Q1 | 37.68 Million USD | 318.94% |
| 2013 FY | - USD | 148.06% |
| 2013 Q1 | -4.16 Million USD | -42.16% |
| 2013 Q3 | 8.38 Million USD | 347.41% |
| 2013 Q2 | 1.87 Million USD | 144.99% |
| 2013 Q4 | 8.99 Million USD | 7.22% |
| 2012 Q3 | -360 Thousand USD | 97.7% |
| 2012 Q1 | -8.55 Million USD | 33.71% |
| 2012 FY | - USD | -204.57% |
| 2012 Q4 | -2.93 Million USD | -714.44% |
| 2012 Q2 | -15.67 Million USD | -83.17% |
| 2011 Q1 | 59.03 Million USD | 2992.56% |
| 2011 Q2 | -5.63 Million USD | -109.55% |
| 2011 Q4 | -12.9 Million USD | -45.03% |
| 2011 FY | - USD | -308.38% |
| 2011 Q3 | -8.9 Million USD | -57.83% |
| 2010 Q3 | 2.14 Million USD | -49.98% |
| 2010 Q1 | -3.64 Million USD | -7.97% |
| 2010 Q2 | 4.28 Million USD | 217.6% |
| 2010 Q4 | 1.9 Million USD | -10.92% |
| 2010 FY | - USD | 121.23% |
| 2009 FY | - USD | 10.34% |
| 2009 Q1 | -9.65 Million USD | 13.42% |
| 2009 Q2 | -9.35 Million USD | 3.12% |
| 2009 Q3 | 1.59 Million USD | 117.07% |
| 2009 Q4 | -3.37 Million USD | -311.27% |
| 2008 Q4 | -11.15 Million USD | -3969.71% |
| 2008 Q3 | -274 Thousand USD | 93.4% |
| 2008 Q2 | -4.15 Million USD | 47.24% |
| 2008 Q1 | -7.86 Million USD | -54.02% |
| 2008 FY | - USD | -269.67% |
| 2007 Q4 | -5.1 Million USD | -113.05% |
| 2007 Q1 | -11.04 Million USD | -18.56% |
| 2007 FY | - USD | 134.35% |
| 2007 Q2 | -9.17 Million USD | 17.01% |
| 2007 Q3 | 39.14 Million USD | 526.9% |
| 2006 FY | - USD | -52.19% |
| 2006 Q3 | -12.92 Million USD | -27.97% |
| 2006 Q2 | -10.09 Million USD | -26.67% |
| 2006 Q1 | -7.97 Million USD | -75.29% |
| 2006 Q4 | -9.31 Million USD | 27.87% |
| 2005 FY | - USD | -7.3% |
| 2005 Q1 | -6.16 Million USD | -16.95% |
| 2005 Q2 | -8.57 Million USD | -39.16% |
| 2005 Q3 | -7.05 Million USD | 17.75% |
| 2005 Q4 | -4.54 Million USD | 35.54% |
| 2004 Q4 | -5.26 Million USD | 14.33% |
| 2004 Q1 | -6.11 Million USD | 34.22% |
| 2004 FY | - USD | 13.12% |
| 2004 Q2 | -7.09 Million USD | -15.95% |
| 2004 Q3 | -6.15 Million USD | 13.31% |
| 2003 Q3 | -6.27 Million USD | 8.98% |
| 2003 Q4 | -9.3 Million USD | -48.27% |
| 2003 Q2 | -6.89 Million USD | -17.07% |
| 2003 Q1 | -5.88 Million USD | 39.24% |
| 2003 FY | - USD | 37.93% |
| 2002 Q4 | -9.69 Million USD | -19.74% |
| 2002 FY | - USD | -233.19% |
| 2002 Q3 | -8.09 Million USD | -47.72% |
| 2002 Q2 | -5.47 Million USD | -51.8% |
| 2002 Q1 | -4.42 Million USD | 5.0% |
| 2001 Q3 | -3.58 Million USD | 7.21% |
| 2001 Q1 | -2.46 Million USD | 10.59% |
| 2001 FY | - USD | -174.83% |
| 2001 Q2 | -3.86 Million USD | -110.58% |
| 2001 Q4 | -3.79 Million USD | -5.99% |
| 2000 FY | - USD | -169.6% |
| 2000 Q4 | -2.73 Million USD | -67.58% |
| 2000 Q3 | -1.73 Million USD | -48.6% |
| 2000 Q1 | -1.21 Million USD | 38.57% |
| 2000 Q2 | -1.48 Million USD | 7.31% |
| 1999 FY | - USD | 317.21% |
| 1999 Q4 | -1.44 Million USD | -20.58% |
| 1999 Q2 | -1.1 Million USD | -10.0% |
| 1999 Q1 | -927.51 Thousand USD | 9.09% |
| 1999 Q3 | -1.29 Million USD | -9.09% |
| 1998 FY | - USD | -200.0% |
| 1998 Q2 | -600 Thousand USD | -16.67% |
| 1998 Q3 | -900 Thousand USD | -28.57% |
| 1998 Q4 | -1 Million USD | -22.22% |
| 1998 Q1 | -500 Thousand USD | -20.0% |
| 1997 Q3 | -300 Thousand USD | -250.0% |
| 1997 Q2 | 200 Thousand USD | 0.0% |
| 1997 Q4 | -500 Thousand USD | -66.67% |
| 1997 FY | - USD | -120.0% |
| 1997 Q1 | 200 Thousand USD | 0.0% |
| 1996 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Aquestive Therapeutics, Inc. | 1.18 Million USD | 18919.543% |
| Collegium Pharmaceutical, Inc. | 308.32 Million USD | 172.146% |
| Journey Medical Corporation | 1.92 Million USD | 11679.75% |
| Dynavax Technologies Corporation | 9.66 Million USD | 2401.335% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | -48.191% |
| Intra-Cellular Therapies, Inc. | -158.85 Million USD | -40.033% |
| Pacira BioSciences, Inc. | 162.89 Million USD | 236.557% |
| PainReform Ltd. | -9.56 Million USD | -2224.663% |
| Petros Pharmaceuticals, Inc. | -4.21 Million USD | -5181.43% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | -5716.493% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | -5716.493% |
| SCYNEXIS, Inc. | 73.47 Million USD | 402.735% |
| Silver Spike Investment Corp. | 7.34 Million USD | 3130.568% |
| China SXT Pharmaceuticals, Inc. | -2.35 Million USD | -9361.763% |
| Alpha Teknova, Inc. | -25.53 Million USD | -771.009% |
| Alvotech | -484.86 Million USD | 54.122% |
| ANI Pharmaceuticals, Inc. | 109.32 Million USD | 303.482% |
| Bright Green Corporation | - USD | Infinity% |
| Embecta Corp. | 245.4 Million USD | 190.647% |
| Safety Shot Inc | -12.18 Million USD | -1725.553% |
| Procaps Group, S.A. | 104.02 Million USD | 313.836% |
| Cosmos Health Inc. | -17.06 Million USD | -1203.772% |
| Theratechnologies Inc. | -10.31 Million USD | -2056.999% |
| Harrow Health, Inc. | 9.72 Million USD | 2387.843% |
| Sonoma Pharmaceuticals, Inc. | -4.52 Million USD | -4815.956% |
| Biofrontera Inc. | -18.45 Million USD | -1105.479% |
| DURECT Corporation | -24.68 Million USD | -801.179% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 326.382% |
| Cronos Group Inc. | -72.14 Million USD | -208.316% |
| OptiNose, Inc. | -15.55 Million USD | -1330.251% |
| Ironwood Pharmaceuticals, Inc. | -924.86 Million USD | 75.948% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | -516.504% |
| RedHill Biopharma Ltd. | 26.26 Million USD | 946.896% |
| Organogenesis Holdings Inc. | 36.03 Million USD | 717.377% |
| Guardion Health Sciences, Inc. | -3.92 Million USD | -5571.263% |
| Cumberland Pharmaceuticals Inc. | -710.85 Thousand USD | -31193.1% |
| Radius Health, Inc. | 38.31 Million USD | 680.65% |
| Universe Pharmaceuticals INC | -3.21 Million USD | -6818.887% |
| ProPhase Labs, Inc. | -14.82 Million USD | -1400.283% |
| Phibro Animal Health Corporation | 84.6 Million USD | 362.918% |
| Procaps Group S.A. | 104.02 Million USD | 313.836% |
| TherapeuticsMD, Inc. | -8.4 Million USD | -2547.863% |
| Viatris Inc. | 3.51 Billion USD | 106.326% |
| Rockwell Medical, Inc. | -4.69 Million USD | -4638.965% |
| Aytu BioPharma, Inc. | -1.01 Million USD | -21880.929% |
| SIGA Technologies, Inc. | 84.15 Million USD | 364.316% |
| Tilray Brands, Inc. | -72.84 Million USD | -205.379% |
| Lifecore Biomedical, Inc. | 812 Thousand USD | 27494.951% |
| Shineco, Inc. | -26.55 Million USD | -737.718% |
| PetIQ, Inc. | 81.48 Million USD | 372.988% |
| Regencell Bioscience Holdings Limited | -3.61 Million USD | -6048.974% |
| Incannex Healthcare Limited | -18.5 Million USD | -1102.156% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 153.46% |
| Alimera Sciences, Inc. | 7.27 Million USD | 3157.27% |
| Shuttle Pharmaceuticals Holdings, Inc. | -3.99 Million USD | -5474.206% |
| Clever Leaves Holdings Inc. | -16.8 Million USD | -1223.774% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | -1010.526% |
| Avadel Pharmaceuticals plc | -149.12 Million USD | -49.168% |
| Hempacco Co., Inc. | -12.77 Million USD | -1641.504% |
| Talphera, Inc. | -9.84 Million USD | -2160.181% |
| Alvotech | -484.86 Million USD | 54.122% |
| Eagle Pharmaceuticals, Inc. | 77.5 Million USD | 387.021% |
| Lantheus Holdings, Inc. | 491 Million USD | 145.304% |
| Currenc Group, Inc. | -1.9 Million USD | -11604.201% |
| Kamada Ltd. | 21.53 Million USD | 1133.004% |
| Indivior PLC | 66 Million USD | 437.041% |
| Evoke Pharma, Inc. | -7.29 Million USD | -2950.439% |
| Flora Growth Corp. | -45.87 Million USD | -384.951% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | -1010.526% |
| Evolus, Inc. | -41.81 Million USD | -432.043% |
| HUTCHMED (China) Limited | 25.52 Million USD | 971.384% |
| Amphastar Pharmaceuticals, Inc. | 241.46 Million USD | 192.124% |
| Akanda Corp. | -27.73 Million USD | -702.025% |